← Leaderboards
Nicola J Mason
University Of Pennsylvania
$7,580,948
Attributed
$12,257,629
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2012–25$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,257,629 · 6
By mechanism
U24$5,350,944 · 2
R01$4,002,418 · 1
U01$2,083,891 · 1
R21$440,000 · 1
K08$380,376 · 1
Top collaborators
- Qi Long9 shared
- Aimee S Payne5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Aimee S Payne$10,136,122
- John R Stanley$7,319,814
- William A. Beltran$14,525,140
- Hansell H Stedman$13,592,979
- Charles H Vite$11,840,835
Others in their field
Top investigators on “Canis Familiaris”
- David Heimbrook · Leidos Biomedical Research, Inc.$33,274,079
- Xinhua Li · Nano Terra, Inc.$23,898,883
- Jeffrey S Chamberlain · University Of Michigan At Ann Arbor$20,518,033
- Ralph Parchment · Leidos Biomedical Research, Inc.$19,740,764
- Dafna Bar-Sagi · State University New York Stony Brook$19,477,294
- Krzysztof Palczewski · University Of California-Irvine$19,305,871
Research focus
Canis FamiliarisClinical TrialsFutureMalignant NeoplasmsTechnologyInnovationCancer PatientT-LymphocyteTranslationsComparativeClinical ResearchImmunotherapyFosteringDesignTrial DesignEnrollmentInsightMouse ModelCellsOncologyMediatingMemberPerformanceImmunologist
Grant awards (23)
Advancing allogeneic CAR-iNKT for the treatment of solid tumors through comparative oncology$692,942
U01 · FY2025 · CA · contact PI
Advancing the Coordinating Center for the Canine Cancer Immunotherapy Network$415,594
U24 · FY2025 · CA · contact PI
Advancing the Coordinating Center for the Canine Cancer Immunotherapy Network$401,993
U24 · FY2024 · CA · contact PI
Advancing allogeneic CAR-iNKT for the treatment of solid tumors through comparative oncology$298,775
U01 · FY2024 · CA · contact PI
Advancing allogeneic CAR-iNKT for the treatment of solid tumors through comparative oncology$575,647
U01 · FY2023 · CA · contact PI
Advancing the Coordinating Center for the Canine Cancer Immunotherapy Network$407,282
U24 · FY2023 · CA · contact PI
Translating cellular immunotherapies for autoimmunity to canine clinical trials$827,495
R01 · FY2022 · AR
Advancing the Coordinating Center for the Canine Cancer Immunotherapy Network$566,719
U24 · FY2022 · CA · contact PI
Advancing allogeneic CAR-iNKT for the treatment of solid tumors through comparative oncology$516,527
U01 · FY2022 · CA · contact PI
Translating cellular immunotherapies for autoimmunity to canine clinical trials$827,495
R01 · FY2021 · AR
Coordinating Center for Canine Immunotherapy Trials and Correlative Studies$567,985
U24 · FY2021 · CA · contact PI
A comparative analysis of human and canine iNKT cells for ACT$238,466
U24 · FY2021 · CA · contact PI
Translating cellular immunotherapies for autoimmunity to canine clinical trials$859,159
R01 · FY2020 · AR
Coordinating Center for Canine Immunotherapy Trials and Correlative Studies$567,292
U24 · FY2020 · CA · contact PI
Coordinating Center for Canine Immunotherapy Trials and Correlative Studies$499,999
U24 · FY2020 · CA · contact PI
Translating cellular immunotherapies for autoimmunity to canine clinical trials$760,992
R01 · FY2019 · AR
Translating cellular immunotherapies for autoimmunity to canine clinical trials$727,277
R01 · FY2018 · AR
Coordinating Center for Canine Immunotherapy Trials and Correlative Studies$1,685,614
U24 · FY2017 · CA · contact PI
Identification of a naturally occurring model for EBV-associated lymphomagenesis$200,000
R21 · FY2013 · AI · contact PI
Identification of a naturally occurring model for EBV-associated lymphomagenesis$240,000
R21 · FY2012 · AI · contact PI
C-Rel in resistance to toxoplasma gondii$127,872
K08 · FY2004 · AI
C-Rel in resistance to toxoplasma gondii$126,252
K08 · FY2003 · AI
C-Rel in resistance to toxoplasma gondii$126,252
K08 · FY2002 · AI